Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. - Wikidata - wikimedia - TriplyDB

Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.

Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.

http://www.wikidata.org/entity/Q34703016

about

Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast.HMGA2 promotes vasculogenic mimicry and tumor aggressiveness by upregulating Twist1 in gastric carcinoma Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model.Decrease in thyroid adenoma associated (THADA) expression is a marker of dedifferentiation of thyroid tissue.Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type Genome-wide analysis of HMGA2 transcription factor binding sites by ChIP on chip in gastric carcinoma cells.Identification of genes differentially expressed in benign versus malignant thyroid tumors Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse Correlated expression of HMGA2 and PLAG1 in thyroid tumors, uterine leiomyomas and experimental models The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma.Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease Integrated network analysis and logistic regression modeling identify stage-specific genes in Oral Squamous Cell Carcinoma Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.Regulation of let-7 and its target oncogenes (Review)Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology.Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene.HMGA2 plays an important role in Cr (VI)-induced autophagy.MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression.High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients.HMGA2 Expression in Renal Carcinoma and its Clinical Significance Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer.HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer.Roles of microRNA let-7b in papillary thyroid carcinoma by regulating HMGA2.siRNA-Mediated Silencing of HMGA2 Induces Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma.MicroRNA-337 regulates the PI3K/AKT and Wnt/β-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2.Expression of high mobility group A2 is associated with poor survival in hepatocellular carcinoma.Thyroid follicular adenomas and carcinomas: molecular profiling provides evidence for a continuous evolution.

P2860

Q33570576-A0F0B427-BCDF-4E66-8AEB-FBA144DDA39A Q33714914-A1AA2389-D074-473B-A6DD-BC614163F979 Q33734313-256E12E7-AF41-4C35-8CAD-933E9F284E2B Q34066111-3841E1AF-9946-40D3-8D52-105F9CAEA53D Q34119524-8A86DE2F-0F65-4E9D-BDEB-BB76A424C11E Q34247211-6EDB8B61-737C-4556-BDC9-6C950B74868B Q34913566-86F4CCEC-66A7-4B66-8EF5-C183036AA2C3 Q35022217-5178496B-3D07-4140-A63D-E7858A7EDFEC Q35091563-F3CB69E9-94BF-4ED2-885A-3676B0A2A2C9 Q35198957-5AC3D825-E26A-4976-B6E5-6EF985089C2C Q35225620-42718D9B-00D7-4608-B79E-CB374EDFE8F8 Q35523700-386E11A9-793F-47D4-8D86-72D927688F51 Q35626938-D90BFC0B-901E-4FC9-ADAC-F9BA9F90BB2E Q35693163-93EA7430-2A36-49C8-9A8E-BBC73D50A01C Q35852065-3C856654-3899-4BDA-B31B-4B9B6C29F1B7 Q36076000-9A068D4F-7A2D-410C-80A7-E2D60A5858CF Q36878690-B2001C83-1954-4BD0-BC99-B94312390455 Q37262636-C4D4F3A6-C9EE-4514-8B74-78C925A3C808 Q37676466-AF86585C-200F-4375-94F1-2E22EA2A8624 Q37996353-5A8087B2-59D9-44A6-9BF6-6C452F67EB20 Q38439427-01387D0D-787E-424A-B1D7-4A3A7E182234 Q38782908-47CB9899-45C5-4B68-9048-DE403CAA69A2 Q38823432-75C50370-1D20-422A-8784-9003D15F29AF Q38852100-AA37D543-C8BB-44A9-91F4-1F810614B2DB Q38868171-1C954DF9-1910-41A2-AA2A-BC023049A97F Q38974180-B5937249-7856-4369-84D9-33B58F134550 Q39248052-EF9946E7-FFA0-4554-8B4B-3D27048F2117 Q47660891-FA33D33C-00F1-4A86-93F8-6C3E5C172D9B Q51506439-869112C1-748E-456E-A3DC-FD2B86138D4E Q52595053-5CE45DEB-05D1-4BDF-98AC-8B905C62290B Q54316822-35075ADE-1BC4-451D-9075-38C19C128399 Q55004058-FF14B281-DB26-40B6-A076-990B9DE0B754

P2860

Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.

http://www.wikidata.org/entity/Q34703016

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@ast

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@en

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@nl

type

label

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@ast

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@en

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@nl

prefLabel

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@ast

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@en

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@nl

P1433

Q34703016-7B08C835-3604-4BB0-AB82-6DD0F0C82428

P1476

Q34703016-CD95A11C-61E1-46FE-B290-57D6601EBA76

P2093

Q34703016-04B87157-F841-412F-85CF-AC6C338607C5

Q34703016-08E7EF6A-74BC-496D-A2EC-73B85ABC55D1

Q34703016-1EF24EBF-5F91-4AD2-81D8-0EE790AFA96B

Q34703016-273F8771-B93C-48F2-BAFB-F0A2C2C67BAA

Q34703016-276697E5-BB03-4C1F-A255-FE825A8E3E95

Q34703016-488AC523-69B7-4DED-B5D9-716C4C9E72A1

Q34703016-68BCE694-5B64-40BF-8C63-D29022A1C77A

Q34703016-B156E6C7-34FA-463E-B4A8-E6E692BFFCC1

P2860

Q34703016-984CF0D7-5AC0-449F-B825-06612FF7D77A

Q34703016-B64FA167-B975-403A-A8BD-4A1F3C86445F

P304

Q34703016-8C6E49D0-8D11-4013-8EAC-2B8C592F4DFC

P31

Q34703016-A7767025-2A0A-4A36-8AA4-9BF37ED8F9ED

P356

Q34703016-67836F96-F0EB-4E03-8E35-8527AD1FDFEF

P433

Q34703016-154156EB-7B87-4961-9E4B-BE43400CA68C

P478

Q34703016-6D72E487-9842-4FA4-A254-FE4027860E91

P577

Q34703016-6F715323-760E-4A7F-8491-2E90B5760657

P5875

Q34703016-03B77E4C-5D63-47A9-80BB-00CC6373BE90

P698

Q34703016-485CF2C1-BA57-4222-8282-CB7BD0E317C4

P356

P1433

Genes, Chromosomes and Cancer

P1476

Upregulation of HMGA2 in thyro ...... lignant follicular neoplasias.

@en

P2093

Anke Meyer

http://www.w3.org/2001/XMLSchema#string

Corinna Stern

http://www.w3.org/2001/XMLSchema#string

Gazanfer Belge

http://www.w3.org/2001/XMLSchema#string

Jörn Bullerdiek

http://www.w3.org/2001/XMLSchema#string

Käte Burchardt

http://www.w3.org/2001/XMLSchema#string

Markus Klemke

http://www.w3.org/2001/XMLSchema#string

Siegfried Loeschke

http://www.w3.org/2001/XMLSchema#string

Werner Wosniok

http://www.w3.org/2001/XMLSchema#string

P2860

HMGI/Y proteins: flexible regulators of transcription and chromatin structure

Continuing controversies in the management of thyroid nodules.

P304

56-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GCC.20505

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5901606

http://www.w3.org/2001/XMLSchema#string

P698

17943974

http://www.w3.org/2001/XMLSchema#string